Stay updated on Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial
Sign up to get notified when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.

Latest updates to the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page
- CheckyesterdayChange DetectedAdded a Locations section listing Delaware and District of Columbia as study sites. The page also removes the separate Delaware Locations and District of Columbia Locations entries and updates the revision to v3.3.3.SummaryDifference0.4%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no visible changes to study details or layout. This appears to be a metadata/versioning update rather than content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check37 days agoChange DetectedGeneral site status/funding notice was removed from the page. The core trial information and study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check51 days agoChange DetectedThe screenshots show only minor UI refresh and updated timestamps; no changes to core study content such as objectives, eligibility, endpoints, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check80 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

- Check87 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cancer Risk on Dapagliflozin vs Other Antidiabetic: Clinical Trial page.